亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors

医学 癌症免疫疗法 免疫疗法 免疫检查点 免疫系统 癌症研究 内科学 癌症 免疫学
作者
Eléonora De Martin,Jean‐Marie Michot,Barbara Papouin,Stéphane Champiat,Christine Mateus,Olivier Lambotte,Bruno Roche,Térésa Antonini,Audrey Coilly,Salim Laghouati,Caroline Robert,Aurélien Marabelle,Catherine Guettier,Didier Samuel
出处
期刊:Journal of Hepatology [Elsevier BV]
卷期号:68 (6): 1181-1190 被引量:557
标识
DOI:10.1016/j.jhep.2018.01.033
摘要

•Acute hepatitis resulting from treatment of metastatic cancer with immune checkpoint inhibitors is rare. •Immune-mediated hepatitis diagnosis requires exclusion of all causes of hepatitis. •Liver histology is paramount for the diagnosis and severity evaluation of liver damage. •Management should be based on biological and histological severity of liver injury. •Immune-mediated hepatitis does not require the systematic use of corticosteroids. Background & Aims Immunotherapy for metastatic cancer can be complicated by the onset of hepatic immune-related adverse events (IRAEs). This study compared hepatic IRAEs associated with anti-programmed cell death protein 1 (PD-1)/PD ligand 1 (PD-L1) and anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) monoclonal antibodies (mAbs). Methods Among 536 patients treated with anti-PD-1/PD-L1 or CTLA-4 immunotherapies, 19 (3.5%) were referred to the liver unit for grade ≥3 hepatitis. Of these patients, nine had received anti-PD-1/PD-L1 and seven had received anti-CTLA-4 mAbs, in monotherapy or in combination with anti-PD-1. Liver investigations were undertaken in these 16 patients, including viral assays, autoimmune tests and liver biopsy, histological review, and immunostaining of liver specimens. Results In the 16 patients included in this study, median age was 63 (range 33-84) years, and nine (56%) were female. Time between therapy initiation and hepatitis was five (range, 1–49) weeks and median number of immunotherapy injections was two (range, 1–36). No patients developed hepatic failure. Histology related to anti-CTLA-4 mAbs demonstrated granulomatous hepatitis including fibrin ring granulomas and central vein endotheliitis. Histology related to anti-PD-1/PD-L1 mAbs was characterised by lobular hepatitis. The management of hepatic IRAEs was tailored according to the severity of both the biology and histology of liver injury: six patients improved spontaneously; seven received oral corticosteroids at 0.5–1 mg/kg/day; two were maintained on 0.2 mg/kg/day corticosteroids; and one patient required pulses and 2.5 mg/kg/day of corticosteroids, and the addition of a second immunosuppressive drug. In three patients, immunotherapy was reintroduced without recurrence of liver dysfunction. Conclusions Acute hepatitis resulting from immunotherapy for metastatic cancer is rare (3.5%) and, in most cases, not severe. Histological assessment can distinguish between anti-PD-1/PD-L1 and anti-CTLA-4 mAb toxicity. The severity of liver injury is helpful for tailoring patient management, which does not require systematic corticosteroid administration. Lay summary Immunotherapy for metastatic cancer can be complicated by immune-related adverse events in the liver. In patients receiving immunotherapy for metastatic cancer who develop immune-mediated hepatitis, liver biopsy is helpful for the diagnosis and evaluation of the severity of liver injury. This study demonstrates the need for patient-oriented management, which could eventually avoid unnecessary systemic corticosteroid treatment. Immunotherapy for metastatic cancer can be complicated by the onset of hepatic immune-related adverse events (IRAEs). This study compared hepatic IRAEs associated with anti-programmed cell death protein 1 (PD-1)/PD ligand 1 (PD-L1) and anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) monoclonal antibodies (mAbs). Among 536 patients treated with anti-PD-1/PD-L1 or CTLA-4 immunotherapies, 19 (3.5%) were referred to the liver unit for grade ≥3 hepatitis. Of these patients, nine had received anti-PD-1/PD-L1 and seven had received anti-CTLA-4 mAbs, in monotherapy or in combination with anti-PD-1. Liver investigations were undertaken in these 16 patients, including viral assays, autoimmune tests and liver biopsy, histological review, and immunostaining of liver specimens. In the 16 patients included in this study, median age was 63 (range 33-84) years, and nine (56%) were female. Time between therapy initiation and hepatitis was five (range, 1–49) weeks and median number of immunotherapy injections was two (range, 1–36). No patients developed hepatic failure. Histology related to anti-CTLA-4 mAbs demonstrated granulomatous hepatitis including fibrin ring granulomas and central vein endotheliitis. Histology related to anti-PD-1/PD-L1 mAbs was characterised by lobular hepatitis. The management of hepatic IRAEs was tailored according to the severity of both the biology and histology of liver injury: six patients improved spontaneously; seven received oral corticosteroids at 0.5–1 mg/kg/day; two were maintained on 0.2 mg/kg/day corticosteroids; and one patient required pulses and 2.5 mg/kg/day of corticosteroids, and the addition of a second immunosuppressive drug. In three patients, immunotherapy was reintroduced without recurrence of liver dysfunction. Acute hepatitis resulting from immunotherapy for metastatic cancer is rare (3.5%) and, in most cases, not severe. Histological assessment can distinguish between anti-PD-1/PD-L1 and anti-CTLA-4 mAb toxicity. The severity of liver injury is helpful for tailoring patient management, which does not require systematic corticosteroid administration.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
机智的觅海完成签到,获得积分10
10秒前
jyy完成签到,获得积分10
42秒前
丘比特的应助被科研通管家采纳,获得10
42秒前
null的应助被科研通管家采纳,获得10
42秒前
null的应助被科研通管家采纳,获得10
42秒前
jyy发布了新的文献求助50
52秒前
WhiteCaramel完成签到 ,获得积分10
1分钟前
积极花瓣完成签到,获得积分10
1分钟前
自觉的孤兰完成签到,获得积分10
1分钟前
生性不爱说话完成签到,获得积分10
1分钟前
1分钟前
山是山三十三完成签到 ,获得积分0
1分钟前
Michelle完成签到 ,获得积分10
1分钟前
怕孤单的雪瑶完成签到,获得积分10
1分钟前
wubin69发布了新的文献求助10
1分钟前
凶狠的映真完成签到,获得积分10
2分钟前
小蘑菇的应助被wubin69采纳,获得10
2分钟前
Ara完成签到,获得积分10
2分钟前
耍酷的手套完成签到,获得积分10
2分钟前
JamesPei的应助被oleskarabach采纳,获得10
2分钟前
2分钟前
敏感兰完成签到,获得积分10
2分钟前
zhanghao完成签到,获得积分10
3分钟前
ZZZ完成签到,获得积分10
3分钟前
breeze完成签到,获得积分10
3分钟前
善良凝荷完成签到,获得积分10
3分钟前
3分钟前
仁爱的如天完成签到,获得积分10
3分钟前
ZZZ发布了新的文献求助10
3分钟前
NexusExplorer的应助被houhoujiang采纳,获得10
3分钟前
Taso17发布了新的文献求助20
3分钟前
foxm完成签到,获得积分10
3分钟前
star发布了新的文献求助30
3分钟前
3分钟前
留胡子的鸿涛完成签到,获得积分10
4分钟前
自由乌冬面完成签到,获得积分10
4分钟前
4分钟前
houhoujiang发布了新的文献求助10
4分钟前
幽nigh完成签到 ,获得积分10
4分钟前
研友_VZG7GZ的应助被Taso17采纳,获得10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185149
求助须知:如何正确求助?哪些是违规求助? 9574052
关于积分的说明 21834129
捐赠科研通 7782677
什么是DOI,文献DOI怎么找? 3434531
关于科研通互助平台的介绍 2558763
邀请新用户注册赠送积分活动 2481208